

compared to the control. In addition, decreased T₃ levels by decreasing DI (28%, p <0.05). Atorvastatin reversed these effects on every parameter studied, reaching control values.

Conclusions: Atorvastatin administration, in addition to prevention, can reverse proliferation, migration, inflammation, and apoptosis in our model, potentially reversing the deregulation of cell growth in the early stages of hepatocarcinogenesis. In addition, AT restores DI activity, potentially balancing thyroid metabolism.

<https://doi.org/10.1016/j.aohep.2024.101663>

P-50 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PATIENTS WITH ACUTE HEPATITIS B VIRUS IN A PUBLIC HOSPITAL IN CHILE FROM 2015 TO 2022.

Herman Aguirre Barahona¹, Marisol Arratia Pinto², Javier Perez Valenzuela³, Belen Soler Masferrer⁴, Camila Lazcano Jorquera⁴, Joaquin Thomas Pozo⁴, Lilian Isla Montoya⁵, Gabriel Mezzano Puentes⁶

- ¹ Servicio Gastroenterología Hospital del Salvador, Santiago, Chile
- ² Residente Gastroenterología Universidad de Chile, Hospital del Salvador, Santiago, Chile
- ³ Departamento Medicina Interna Clínica Universidad de los Andes, Santiago, Chile
- ⁴ Residente Medicina Interna Universidad de Chile, Hospital del Salvador, Santiago, Chile
- ⁵ Enfermera Policlínico Hepatitis Virales Hospital del Salvador, Santiago, Chile
- ⁶ Servicio Gastroenterología, Hospital Del Salvador; Centro De Enfermedades Digestivas, Clínica Universidad De Los Andes, Santiago, Chile

Conflict of interest: No

Introduction and Objectives: Since Chile is a low endemic Hepatitis B virus (HBV) country, most cases present as acute infection that resolves spontaneously (95%). There is scarce literature describing the demographic characteristics and serological follow-up of patients with acute HBV infection in Chile.

The objective is to describe demographic, clinical, laboratory and serological characteristics of patients evaluated in the viral hepatitis polyclinic of a Chilean public hospital. To evaluate indication criteria, received treatments, and surrogate markers of therapeutic objectives.

Patients / Materials and Methods: Observational, retrospective study including adults with acute HBV infection, without immunodeficiency, controlled in hepatology policlinic between 2015 and 2022 at Hospital del Salvador. Descriptive statistics were used to determine the demographic characteristics of this population, criteria for indication of antiviral therapy and surrogate markers of therapeutic targets.

Results and Discussion: 180 clinical records were reviewed. 147 were excluded: poor treatment adherence and follow-up (30), deceased (59), chronic HBV infection (39) and immunodeficiency (19). 33 patients were included in the analysis, with mean age of 32.3 years and 69.6% being men. Sexual transmission was the most frequent transmission mechanism (48%). There were no cases with cirrhosis at the time of diagnosis. 6 patients (18.1%) required antiviral treatment due to severity, being entecavir the antiviral most frequently prescribed. 36.3% achieved ALT normal levels, most of them at the third month. 39.3% achieved loss of the HBV surface antigen (HBsAg).

Conclusions: Most patients achieved loss of HBsAg, however, many had no follow-up HBsAg studies or did not adhere to medical controls. Only 1 patient was diagnosed as chronic infection during

follow-up. Follow-up and adherence to medical controls in patients with acute HBV infection need to be improved.

TREATMENT N: 33 PATIENTS WITH HBV ACUTE INFECTION	
Treatment indication criteria	N (%)
HBV chronic hepatitis with persistent ALT >1.1 above normal level and viral load HVB >2.000 UI/mL	1 (3.03)
No treatment indication	27 (81.81)
Severe acute hepatitis with or without liver failure	5 (15.15)
Antiviral prescription n= 6	
1. ENTECAVIR	6 (100%)
TREATMENT AND FOLLOW-UP RESULTS	
ALT level normalization (< 55 UI/mL)	
1. Yes	12 (36.36)
2. Normal baseline level	6 (18.18)
3. No follow-up	13 (39.39)
4. No ALT baseline levels	2 (6.06)
Time to ALT normalization	
1. Month 3	7 (21.21)
2. Month 6	2 (6.06)
3. Month 12	1 (3.03)
4. Month 18	2 (6.06)
5. Normal prior to first control	3 (9.09)
6. No follow-up	18 (54.54)
HBsAg loss	
1. Yes	13 (39.39)
2. No	1 (3.03)
3. No follow-up	19 (57.57)
Time to HBsAg loss	
1. Month 3	6 (18.18)
2. Month 6	5 (15.15)
3. Month 12	1 (3.03)
4. Month 18	1 (3.03)
5. No follow-up	19 (57.57)
6. Persistent positive HBsAg	1 (3.03)

Clinical and serological characteristics of patients with acute HBV infection.

<https://doi.org/10.1016/j.aohep.2024.101664>

P-51 TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS), EXPERIENCE IN A UNIVERSITY CENTER

Caterina Chesta Alegría¹, Álvaro Urzúa Manchego¹, Víctor Henríquez Auba¹, Patricio Palavecino Rubilar², Nicolás Martínez Roje², Tomás Cermenati Bahrs², Claudio Lema Olivares², Máximo Cattaneo Buteler¹, Juan Pablo Roblero Cum¹, Jaime Poniachik Teller¹

- ¹ Departamento de Gastroenterología, Hospital Clínico Universidad de Chile, Santiago, Chile
- ² Departamento de Radiología, Hospital Clínico Universidad de Chile, Santiago, Chile

Conflict of interest: No

Introduction and Objectives: Transjugular intrahepatic portosystemic shunt (TIPS) is a procedure that diverts portal blood flow to the hepatic vein with the aim of reducing portal hypertension, being an alternative for managing its complications, such as variceal gastrointestinal bleeding and ascites, in both cirrhotic and non-cirrhotic patients. *Objetives:* To characterize patients who underwent TIPS between January 2007 and July 2024 at the Hospital Clínico De la Universidad de Chile

Patients / Materials and Methods: Observational, retrospective cohort study. 39 patients medical records who underwent the procedure during the specified period were reviewed.

Results and Discussion: 39 patients were analyzed, 53.8% of whom were men, with an average age of 60.7 years. The procedure was performed in 51% (20/39) of the patients within a period of just 4 years (2019 to 2024). The main indication was secondary to variceal